Search Results for "Xenon Roche Deal"
Matching Channels
Roche is the 5th largest pharmaceutical company in the world, based on annual sales, which were recorded at $36,017m in 2009. The pharmaceutical products of Roche are major players in the followin...
Digoxin Globulin ovine Fab Roche
Interleukin-2 receptor Mab rDNA Roche
Top 50 Biopharma Products 2011
Ronald A. Rader, president of the Biotechnology Information Institute provided Contract Pharma a list of the Top 57 Biopharma Products by 2011 revenues (in millions). Mr. Rader subscribes to the sam...
Matching News
Teva collaborates with Xenon Pharmaceuticals in $376 million deal for pain drug
Teva Pharmaceutical Industries and Xenon Pharmaceuticals have entered into a collaborative development and exclusive worldwide license for XEN402. XEN402 is currently in clinical development for a var...
Merck in pharma licensing and option deal with Xenon
Big pharma company, Merck, in pharma licensing deal with Xenon stemming from a previous option agreement. Xenon announced that the big pharma company has exercised its pharma licensing option to excl...
Xenon Feels No Pain After $41M Upfront From Teva
Teva and Xenon collaborate to develop the Canadian company’s lead pain product; the deal could net Xenon as much as $376 million and will fit snugly into the Israeli company’s new focus.
Teva, Xenon sign licensing deal for pain drug
Teva Pharmaceutical Industries and Xenon Pharmaceuticals have signed licensing agreement for the development of XEN402 to treat painful disorders.
Teva Pharmaceutical and Xenon Pharmaceuticals in a pact for XEN402
Teva Pharmaceutical Industries and Xenon Pharmaceuticals have entered into a collaborative development and exclusive worldwide license for XEN402. XEN402 is currently in clinical development for a var...
Teva and Xenon Announce Teva's World Wide License of Xenon's Pain Drug XEN402
XEN402 is a Strategic Fit for Teva's Commercial, R&D and Technology focus in CNS and Pain JERUSALEM & BURNABY, British Columbia--(BUSINESS WIRE)--Dec 11, 2012 - Teva Pharmaceutical Industries...
Matching PubMed Articles
Xenon fails to inhibit capsaicin-evoked CGRP release by nociceptors in culture.
To investigate whether the xenon-induced inhibition of the transient receptor potential vanilloid type 1 (TRPV1) ion channel in rat dorsal root ganglion (DRG) neurons reduces nociceptive processing, w...
Deal watch: Chiasma and Roche partner in oral peptide drug delivery.
Observation of a barium xenon exciplex within a large argon cluster.
Spectroscopic measurements provide fluorescence and excitation spectra of a single barium atom codeposited with xenon atoms on argon clusters of average size approximately 2000. The spectra are studie...
The solubility of xenon in liquid n-pentane and n-hexane has been studied experimentally, theoretically, and by computer simulation. Measurements of the solubility are reported for xenon + n-pentane a...
The extracellular signal-regulated kinase (ERK) is involved in the cytokine production of immune cells. In this study, we show the influence of xenon on phosphatase activity, ERK 1/2 signalling and cy...
